Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386707 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL21286125 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1241324 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1241323 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL19964151 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL139880 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL20312947 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1372634 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL30868937 | 0.97 | NR1H2 (0.40) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL6577745 | 0.92 | NR1H2 (0.41) | NR1H2SRCMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-4565579-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | Theras, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-0394991-B1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0545290-A1 | Aminoalkylpyrrolidinylthiocarbapenem derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0544307-A1 | Alkylaminoakylpyrrolidinylthiocarbapenem derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-02 | — | — | EP | disclosed |
| EP-0272456-B1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | disclosed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4822787-A | 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0272456-A1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NR1H2 3543/4885SRC 3128/4885ABCB1 637/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | NR1H2 3184/4885SRC 512/4885ABCB1 2057/4885 |
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | NR1H2 1693/4885SRC 260/4885ABCB1 793/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885ABCB1 797/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NR1H2 3543/4885SRC 3128/4885ABCB1 637/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885ABCB1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.